Ketone Ester Supplement for People Hospitalized With Acute Heart Failure
Tests a ketone ester supplement against placebo in adults hospitalized with acute heart failure.
Plain-language title generated from the registry record
Registry title: Ketone Ester for Treatment Of Acute Heart Failure
Key facts
- Where
- Edmonton, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in hospital with acute heart failure, admitted for less than 48 hours, who have signs of fluid build-up and a high NT-proBNP level.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Acute heart failure with breathlessness on effort or at rest, plus at least two of: fluid on chest X-ray, crackles on listening to the lungs, clearly relevant swelling, or raised neck vein pressure. Admitted to hospital for less than 48 hours.
- Biomarker or test result
- NT-proBNP of 1000 pg/ml or higher; estimated glomerular filtration rate above 15 mL/min/1.73m²
Main reasons for not taking part
- Type 1 diabetes
- On mechanical circulatory support
- On more than one inotrope, or on inopressors
- On dialysis
- Non-functioning enteral tract (the gut cannot be used for feeding)
Read by machine on 10 November 2026.
Where in Canada
- University of AlbertaEdmonton, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Alberta
- Trial code
- NCT07434466
- Record updated
- 9 November 2026
- Original description
Ketones have been suggested to have significant physiological effects in patients with heart failure. Potential mechanisms for these effects include energy provision for the failing heart and direct protective effects on other organs. Despite the strong physiological rationale, the acute effects of ketone therapy in patients with acute heart failure (AHF) is unclear. AHF is a major healthcare issue, with in-hospital mortality exceeding 10%. Therefore, we propose a vanguard randomized controlled trial to assess the effects of ketone esters in patients with AHF. Sixty patients hospitalized with AHF will be randomized to receive either 25 grams of ketone esters three times per day or a matching placebo for five days, or until death or hospital discharge. We hypothesize that ketone therapy will improve markers of systemic congestion and heart failure symptoms. Primary endpoint will be changes in NT-proBNP levels during therapy. Secondary endpoints will be KCCQ scores, and hemodynamic profile as assessed by echocardiogram. Exploratory endpoints will clinical outcomes including mortality, need for intensive care unit admission, among others.Read full original descriptionShow less
KETO-AHF: Ketone Ester for Treatment Of Acute Heart Failure: A Vanguard Randomized Controlled Trial
Ketones have been suggested to have significant physiological effects in patients with heart failure. Potential mechanisms for these effects include energy provision for the failing heart and direct protective effects on other organs. Despite the strong physiological rationale, the acute effects of ketone therapy in patients with acute heart failure (AHF) is unclear. AHF is a major healthcare issue, with in-hospital mortality exceeding 10%. Therefore, we propose a vanguard randomized controlled trial to assess the effects of ketone esters in patients with AHF. Sixty patients hospitalized with AHF will be randomized to receive either 25 grams of ketone esters three times per day or a matching placebo for five days, or until death or hospital discharge. We hypothesize that ketone therapy will improve markers of systemic congestion and heart failure symptoms. Primary endpoint will be changes in NT-proBNP levels during therapy. Secondary endpoints will be KCCQ scores, and hemodynamic profile as assessed by echocardiogram. Exploratory endpoints will clinical outcomes including mortality, need for intensive care unit admission, among others.
Domain-Specific Inclusion Criteria:; Primary diagnosis of AHF with dyspnea on exertion or at rest, and at least two of the following: congestion on chest radiograph, rales on chest auscultation, clinically relevant edema, or an elevated jugular venous pressure [21]; Admitted to the hospital for less than 48 hours; Estimated glomerular filtration rate above 15 mL/min/1.73m²; NT-proBNP ≥ 1000 pg/ml; Domain-Specific Exclusion Criteria:; Type 1 diabetes mellitus; Patients on mechanical circulatory support; Patients on more than one inotrope or on inopressors; Patients on dialysis; Patients with non-functioning enteral tracks.